Abstract:BACKGROUNDThe organization and recanalization of thrombi is a dynamic and complex process. The aim of this research was to study the cotherapeutic effect of stem cell transplantation and gene transfection on chronic venous thrombosis.METHODSWe constructed a recombinant adenoviral vector carrying the vascular endothelial growth factor 165 (VEGF165) gene by using the pAdEasy system, which was subsequently identified and amplified. Simultaneously, endothelial progenitor cells (EPCs) were isolated from rat bone marrow using Ficoll, cultured in EBM-2MV medium, and identified. Then, the cells were transfected with the recombinant Ad-VEGF165. The EPCs were labeled with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (Dil) before transplantation. A rat model of chronic vein thrombosis was developed by partial ligation of the inferior vena cava. The rats were randomly divided into 4 groups (n = 25, each): A, Ad-VEGF165/EPC-transplantation group received 1 ml (10(6)) of Ad-VEGF165/EPCs; B, EPC-transplantation group received 1 ml (10(6)) of EPCs; C, Ad/EPC-transplantation group received 1 ml (10(6)) of Ad/EPCs; D, control group received 1 ml of the transplantation medium. The thrombi and adjacent caval walls were harvested 28 days after transplantation; real-time quantitative polymerase chain reaction was used to detect the expression level of vascular endothelial growth factor (VEGF) mRNA; and western blotting was used to measure changes in VEGF protein expression. Hematoxylin-eosin staining and immunohistochemical staining were performed to detect recanalization. Neovascularization was detected by immunohistochemical staining using the antibody for von Willebrand factor (vWF), which is a component of endothelial cells. The capillary density was quantitatively determined by counting the capillaries under a high-power microscope.RESULTSThe Ad-VEGF165 was constructed, and bone-marrow-derived EPCs were cultivated and successfully identified. We determined the optimum transfection ratio that promoted the growth of EPCs. After transfection, the EPCs secreted the VEGF protein. After transplantation, the in vivo survival of EPCs and their differentiation into endothelial cells were determined by detecting the fluorescence associated with the Dil stain. VEGF mRNA was expressed in groups A, B, C and D after transplantation, and the VEGF mRNA level in group A was significantly higher than those in groups B, C and D (P < 0.05); the VEGF mRNA levels in groups B and C were significantly higher than those in group D (P < 0.05), and there was no statistical significance between the VEGF mRNA levels in groups B and C. The recanalization capillary density in group A was significantly higher than those in groups B, C (P < 0.05) and D (P < 0.01); the recanalization capillary densities in groups B and C were significantly higher than that in group D (P < 0.05). Moreover, there was no statistical significant difference between the values for groups B and C.CONCLUSIONSThe EPCs were successfully transfected by Ad-VEGF165. A suitable transfection ratio can improve the efficiency of EPCs and the possibility of promotion of angiogenesis after transplantation. Transfected EPCs caused accelerated organization and recanalization of vein thrombi.

Local Epression and Thrombolysis of Retroviral Vector with Tissue Type Plasminogen Activator Gene

[Effect of VEGF Gene Transfer on the Bleomycin-Induced Pulmonary Hypertension in Immature Rabbits].

Gene Transfer of Vascular Endothelial Growth Factor Reduces Bleomycin-Induced Pulmonary Hypertension in Immature Rabbits.

Novel Distribution Pattern of Fibrinolytic Components in Rabbit Tissues Extract: a Preliminary Study

Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.

Gene transfer of tissue plasminogen activator mediated by pseudotyped retroviral vector and its effect on smooth muscle cell proliferation

Retroviral Vector-Mediated Transfer and Expression of Human Tissue Plasminogen Activator Cdna in Bovine Brain Endothelial Cells

[Study on inhibiting the intimal hyperplasia after rabbit artery injury by local transfection of tissue-type plasminogen activator gene].

[To Study the Effects of Local Co-Transfection Vascular Endothelial Growth Factor165 and Tissue-Type Plasminogen Activator Genes on Inhibiting Intimal Hyperplasia after Operation Injury Artery in Rabbits].

In vivo expression of human tissue-plasminogen activator transfected AGZY83-a cells implanted in mice

[Effects of Platelet Derived Growth Factor Antisense Oligodeoxynucleotides and Tissue-Type Plasminogen Activator Gene Transfection on Inhibition of Intimal Proliferation].

Experimental Study on Establishing Eukaryotic Expression Vector Pcdna3.1(+) TPA and Its Expressing Activity in Human Skin Fibroblists.

Retroviral vector mediated vascular endothelial growth factor gene therapy for experimental rabbits with cerebral ischemia

Construction and Biological Activities of Human Tpa Eukaryotic Expression Plasmid.

Construction of Eukaryotic Expression Plasmid Containing Tpa Genes and Its Expression in Transfected VSMCs

[Effect of Nanoparticle with Vascular Endothelial Growth Factor Gene Transferred into Ischemic Myocardium: Experiment with Rabbits].

Video Microscope Recording of the Dynamic Course of Thrombosis and Thrombolysis of the Retinal Vein in Rabbits.

Administration of a new nano delivery system coated with Tirofiban to prevent early thrombosis of vein graft

[The in Vivo and in Vitro Effects on Neovascularization of VEGF Gene Transfer with a New Pseudotyped Raav1 Vector].

Transplantation of VEGF165-gene-transfected Endothelial Progenitor Cells in the Treatment of Chronic Venous Thrombosis in Rats.

Construction of retroviral vector with tissue type plasminogen activator gene and culture of pure packaging cell line